Renata PLC (DSE:RENATA)

Bangladesh · Delayed Price · Currency is BDT

418.30

-1.60 (-0.38%)

At close: Nov 4, 2026

Market Cap	47.98B -3.1%
Revenue (ttm)	46.20B +7.7%
Net Income	3.64B +64.0%
EPS	31.76 +64.0%
Shares Out	114.70M
PE Ratio	13.17
Forward PE	13.70
Dividend	5.50 (1.32%)
Ex-Dividend Date	Nov 16, 2026

Volume	11,924
Open	n/a
Previous Close	419.90
Day's Range	415.00 - 424.20
52-Week Range	372.00 - 488.00
Beta	0.03
Analysts	Strong Buy
Price Target	615.05 (+47.04%)
Earnings Date	Oct 29, 2026

About Renata

Renata PLC engages in the manufacture, marketing, and distribution of pharmaceuticals, animal health medicines, oncology-based, agro-based, and consumer products in Bangladesh and Portugal. The company offers generic products, including amantadine, clindamycin, clindamycin, colchicine, dipyridamole, escitalopram, fludrocortisone acetate, hydrocortisone, prednisolone, propylthiouracil, sertraline hydrochloride, terbinafine, and topiramate tablet and capsules. It also offers specialty products, such as SHK-024, an antidepressant, and SHK 007, to ... [Read more]

Industry Pharmaceutical Preparations

Founded 1972

Employees 8,681

Stock Exchange Dhaka Stock Exchange

Ticker Symbol RENATA

Full Company Profile

Financial Performance

In fiscal year 2026, Renata's revenue was 46.20 billion, an increase of 7.71% compared to the previous year's 42.89 billion. Earnings were 3.64 billion, an increase of 64.02%.

Financial Statements

Analyst Summary

According to 2 analysts, the average rating for RENATA stock is "Strong Buy." The 12-month stock price target is ৳615.05, which is an increase of 47.04% from the latest price.

Price Target

৳615.05

(47.04% upside)

Analyst Consensus: Strong Buy

Stock Forecasts